Kura Oncology, Inc.
KURA
$5.95
$0.223.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 482.66% | -- | -- | -- | -- |
| Gross Profit | -295.19% | -- | -- | -- | -- |
| SG&A Expenses | 42.49% | 52.49% | 37.77% | 31.56% | 23.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.77% | 49.02% | 41.05% | 34.91% | 27.87% |
| Operating Income | -10.75% | -16.52% | -41.05% | -34.91% | -27.87% |
| Income Before Tax | -6.88% | -12.67% | -38.19% | -29.95% | -22.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.21% | -13.99% | -38.19% | -29.95% | -22.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.21% | -13.99% | -38.19% | -29.95% | -22.28% |
| EBIT | -10.75% | -16.52% | -41.05% | -34.91% | -27.87% |
| EBITDA | -10.82% | -16.61% | -41.27% | -35.07% | -27.97% |
| EPS Basic | 3.95% | 2.90% | -16.69% | -8.79% | -6.72% |
| Normalized Basic EPS | 3.60% | 2.48% | -24.18% | -16.07% | -14.03% |
| EPS Diluted | 3.95% | 2.90% | -16.69% | -8.79% | -6.72% |
| Normalized Diluted EPS | 3.60% | 2.48% | -24.18% | -16.07% | -14.03% |
| Average Basic Shares Outstanding | 12.93% | 17.71% | 18.22% | 19.15% | 14.28% |
| Average Diluted Shares Outstanding | 12.93% | 17.71% | 18.22% | 19.15% | 14.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |